Centre Of Research Excellence In Medicines Intelligence
Funder
National Health and Medical Research Council
Funding Amount
$2,500,000.00
Summary
The NHMRC Centre of Research Excellence in Medicines Intelligence is a co-ordinated research program that will accelerate the development and translation of evidence on prescribed medicines use and outcomes for regulators and payers. The CRE is perfectly placed to embrace the national ‘call to action’ from the Health Minister's recent announcement to establish Quality Use of Medicine Safety as a National Health Priority.
Most eye diseases have a genetic contribution, whether rare disorders affecting children such as retinoblastoma or congenital cataracts through to common disorders of older people such as myopia, age-related macular degeneration or glaucoma. We will continue our successful research to find genes that cause these diseases and use this to improve patient care and prevent blindness. We will work out how families can use this genetic information to participate in trials to develop new treatments.
Antibiotic resistance is a looming public health crisis. New antibiotics with new mechanisms of action are desperately needed. The long-term goal of this research is to develop new drugs that disarm bacteria to overcome the problem of antibiotic resistance.
Discovery Early Career Researcher Award - Grant ID: DE240100816
Funder
Australian Research Council
Funding Amount
$444,000.00
Summary
Probing dark energy with the largest 3D Map of the Universe. Dark Energy is one of the most profound mysteries of modern physics. It makes up about 70 percent of the Universe, but no compelling theory can explain its nature. This project aims to measure the properties of Dark Energy with unprecedented accuracy: an order of magnitude better than the state of the art. It aims to accomplish this by extracting information from the largest 3D map of the cosmos, built with the optical spectra of 35 mi ....Probing dark energy with the largest 3D Map of the Universe. Dark Energy is one of the most profound mysteries of modern physics. It makes up about 70 percent of the Universe, but no compelling theory can explain its nature. This project aims to measure the properties of Dark Energy with unprecedented accuracy: an order of magnitude better than the state of the art. It aims to accomplish this by extracting information from the largest 3D map of the cosmos, built with the optical spectra of 35 million galaxies, observed by the Dark Energy Spectroscopic Instrument. This project will foster Australia's historic leadership and investments in galaxy surveys via unique international partnerships, and produce cutting-edge tools for big data analyses with important applications in a wide range of industries.Read moreRead less
Targeted Development Of AMPK Β2-isoform Allosteric Activators
Funder
National Health and Medical Research Council
Funding Amount
$898,147.00
Summary
Sedentary lifestyles and consumption of high energy foods has led to dramatic increases in the incidence of diseases associated with metabolic dysregulation e.g. type 2 diabetes. An attractive drug target to treat these diseases is AMP-activated protein kinase (AMPK) which functions as a cellular fuel gauge. We have discovered a new drug that crucially activates the form of AMPK found in metabolically active organs. We aim to develop this drug to unlock new therapeutic opportunity.
Re-EValuating The Inhibition Of Stress Erosions (REVISE): Gastrointestinal Bleeding Prophylaxis In ICU
Funder
National Health and Medical Research Council
Funding Amount
$2,955,164.00
Summary
Around 50,000 patients in Australian Intensive Care Units receive a drug called pantoprazole each year with the aim of preventing bleeding from the gut. Recent research suggests this practice is ineffective and may harm patients by increasing their risk of serious infections. We will perform a definitive study to determine whether the widespread use of pantoprazole is beneficial or harmful.